Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of Ibrexafungerp on Dabigatran Pharmacokinetics in Healthy Subjects
NCT04092725Phase 1Completed
- Sponsor
- SCYNEXIS, Inc.
- Start
- Sep 2019
- Primary completion
- Jan 2020
- Modality
- Allosteric Modulators
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of ibrexafungerp in vulvovaginal candidiasis (VVC), invasive candidiasis and aspergillosis (2 arms), sponsored by SCYNEXIS, Inc. Primary endpoint: Area Under the Curve at 17 days. Started Sep 2019; status: completed.
02
Drugs
ibrexafungerp
03
Conditions
vulvovaginal candidiasis (VVC)invasive candidiasisaspergillosis
Beyond the preview
Go deeper on NCT04092725.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04092725.